US3369968A - Composition and method of absorbing gas in teh intestine - Google Patents
Composition and method of absorbing gas in teh intestine Download PDFInfo
- Publication number
- US3369968A US3369968A US327842A US32784263A US3369968A US 3369968 A US3369968 A US 3369968A US 327842 A US327842 A US 327842A US 32784263 A US32784263 A US 32784263A US 3369968 A US3369968 A US 3369968A
- Authority
- US
- United States
- Prior art keywords
- magnesium hydroxide
- intestinal tract
- magnesium
- medicament
- intestine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F5/00—Compounds of magnesium
- C01F5/02—Magnesia
- C01F5/06—Magnesia by thermal decomposition of magnesium compounds
- C01F5/08—Magnesia by thermal decomposition of magnesium compounds by calcining magnesium hydroxide
Definitions
- the present invention pertains generally to the use of magnesium hydroxide or magnesium oxide to react with carbon dioxide in the intestinal tract to form magnesium carbonate. Included in the present invention are novel means and methods of providing relief from discomfort due to abnormal or excessive quantities of carbon dioxide gas in the intestinal tract, without laxative action associated with the administration of magnesium containing antacids.
- the stomach becomes acid as gastric juice containing hydrochloric acid is secreted into it.
- this acid juice mixed with foods, enters the duodenum, it is neutralized with fluid containing sodium bicarbonate.
- the free acid and the bicarbonate form carbonic acid which has limited stability, especially at body temperature in body fluids, and some carbon'dioxide gas forms, sometimes resulting in discomfort.
- Carbon dioxide gas when formed by fermentation of carbohydrates in the intestinal tract adds to the discomfort. See my copendin application directed to the treatment of flatulence in people, Ser. No. 318,821, filed Oct. 25, 1963.
- the present invention covers means of decreasing the flatulence caused by the additional gas released by the neutralization process in the duodenum as well as by fermentation gas.
- antacids have been marketed and are on the market for the purpose of neutralizing acidity in the stomach.
- aqueous magnesium hydroxide sold in the form of Milk of Magnesia for antacid and laxative purposes.
- Some laxative action is always involved in products of this type as the magnesium hydroxide reacts with the hydrochloric acid in the stomach to form the readily soluble magnesium chloride, which in turn has a laxative eflect as it moves down the intestinal tract.
- the use of Milk of Magnesia or the like is obviously also contra-indicated. This also applies when undesirable side reactions are encountered due to partial absorption of the water-soluble magnesium salts formed, for example, upon oral administration of antacids such as magnesium hydroxide or oxide.
- enteric coated dosage units e.g. tablets, capsules, pills and the like, containing magnesium hydroxide or.magnesium oxide or mixtures of the same.
- enteric coating used should be of the commercially available conventional types which release the medicament in the intestinal tract after passage through the stomach.
- Enteric coatings of the preferred type, of which cellulose acetate phthalate, is illustrative do not release the medicament until the intestinal fluid is free or substantially free from available hydrochloric acid, e.g. do not release the medicament until the pH of the intestinal fluid is at least about 5.56 or higher.
- magnesium hydroxide and magnesium oxide can be used in the enteric coated dosage units of the present invention. Their reaction with the carbon dioxide gas, however, may be somewhat retarded or not as rapid as desired in some cases, due to the fact that the pH of the fluids in the duodenum and lower intestinal tract is for the most part nearly neutral.
- the freeze-dried magnesium hydroxide product due to its high activity, can also be used to advantage where desired as a simple antacid or laxative in dosage unit form without the enteric coating.
- the highly reactive freeze-dried product for example, can be sealed in strips, either foil or transparent, in antacid or laxative doses.
- the dosage units which can be flavored, can be administered as such or added to water to make an instant Milk of Magnesia type product. Both the enteric coated products and the freeze-dried product have an advantage over liquid products in that they pose no freezing problem during transportation in winter.
- magnesia magma e.g. made up of about 30% Mg(OH) and 70% H O
- a flask suspended in an acetone-Dry Ice mixture.
- the flask is removed from the freezing mixture and a high vacuum applied so that the magma dries from the frozen state without melting.
- the vacuum is disconnected.
- the resulting freeze-dried magnesium hydroxide product is next tabletted by conventional means with starch and lactose or like pharmaceutical diluents along with binders and lubricants to form compressed tablets containing about 0.5 gm. of magnesium hydroxide per tablet.
- the tablets are then finally enteric coated with cellulose acetate phthalate or other suitable enteric coating so that when administered orally the intestinal fluid does not reach the tablet contents until the pH of the fluid is at least about 5.5-6 or higher, i.e. when there is substantially no free HCl present in the fluid.
- EXAMPLE II This example is in accordance with Example I, except that commercial magnesium hydroxide (NF) is used in place of the freeze-dried magnesium hydroxide product.
- the tablet is enteric coated to provide for the release of the magnesium hydroxide after the pH of the intestinal fluid reaches at least about pH 5.5-6.
- EXAMPLE III This example is in accordance with Example II, except that magnesium oxide is used in place of magnesium hydroxide.
- EXAMPLE IV This example is in accordance with Example I, except that the tablet containing the freeze-dried magnesium hydroxide product is not enteric coated. With tablets 01. this type, the dose as an antacid is 12 tablets and the dose as a laxative is 3-4 tablets.
- EXAMPLE V flatulence-causing gases through the intestine as magnesium carbonate in solid form. It also will be apparent from the above that as the dosage units disintegrate and release the magnesium hydroxide or oxide medicamenis only after the pH of the intestinal contents are above the value Where available hydrochloric acid would be negligible, no significant amounts of soluble magnesium compounds form. This last feature as noted above, is important Where side effects caused by absorption of magnesium are to be avoided and laxative action is contraindicated.
- An enteric coated dosage unit containing as an essential ingredient a medicament selected from the group consisting of magnesium hydroxide and magnesium oxide in an amount sufficient to provide relief from discomfort due to excessive carbon dioxide in the human intestinal tract, said enteric coating being an enteric coating Which will release the medicament in the intestinal tract when the intestinal fluid is substantially free from hydrochloric acid.
- the method of providing relief from discomfort due to excessive carbon dioxide in the intestinal tract Without laxative action which comprises orally administering to persons an enteric coated tablet containin as an essential ingredient a medicament in an effective amount selected from the group consisting of magnesium hydroxide and magnesium oxide, said enteric coating being an enteric coating Which Will release the medica' ment in the intestinal tract When the intestinal fluid is substantially free from hydrochloric acid.
- a dosage unit adaptable for use as an antacid and laxative consisting essentially of magnesium hydroxide prepared by freeze-drying Milk of Magnesia.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Thermal Sciences (AREA)
- Geology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
United States Patent 3,369,968 CQMPOSITION AND METHOD OF ABSORBING GAS IN THE INTESTINE Walton J. Smith, 410 E. 57th St., New York, N.Y. 10022 No Drawing. Filed Dec. 3, 1963, Ser. No. 327,842 4 Claims. (Cl. 167-55) The present invention pertains generally to the use of magnesium hydroxide or magnesium oxide to react with carbon dioxide in the intestinal tract to form magnesium carbonate. Included in the present invention are novel means and methods of providing relief from discomfort due to abnormal or excessive quantities of carbon dioxide gas in the intestinal tract, without laxative action associated with the administration of magnesium containing antacids.
It is well-known that the stomach becomes acid as gastric juice containing hydrochloric acid is secreted into it. When this acid juice, mixed with foods, enters the duodenum, it is neutralized with fluid containing sodium bicarbonate. The free acid and the bicarbonate form carbonic acid which has limited stability, especially at body temperature in body fluids, and some carbon'dioxide gas forms, sometimes resulting in discomfort. Carbon dioxide gas when formed by fermentation of carbohydrates in the intestinal tract adds to the discomfort. See my copendin application directed to the treatment of flatulence in people, Ser. No. 318,821, filed Oct. 25, 1963. The present invention covers means of decreasing the flatulence caused by the additional gas released by the neutralization process in the duodenum as well as by fermentation gas.
Many so-called antacids have been marketed and are on the market for the purpose of neutralizing acidity in the stomach. One of these, which has been available for decades, is aqueous magnesium hydroxide sold in the form of Milk of Magnesia for antacid and laxative purposes. Some laxative action is always involved in products of this type as the magnesium hydroxide reacts with the hydrochloric acid in the stomach to form the readily soluble magnesium chloride, which in turn has a laxative eflect as it moves down the intestinal tract. In view of this, when antacid action only is desired and laxative action is contra-indicated, the use of Milk of Magnesia or the like is obviously also contra-indicated. This also applies when undesirable side reactions are encountered due to partial absorption of the water-soluble magnesium salts formed, for example, upon oral administration of antacids such as magnesium hydroxide or oxide.
In investigations in this field it was discovered that flatulence caused by the generation of carbon dioxide in the intestinal tract can be controlled, without any substantial laxative action, by the administration of enteric coated dosage units, e.g. tablets, capsules, pills and the like, containing magnesium hydroxide or.magnesium oxide or mixtures of the same. The enteric coating used should be of the commercially available conventional types which release the medicament in the intestinal tract after passage through the stomach. Enteric coatings of the preferred type, of which cellulose acetate phthalate, is illustrative, do not release the medicament until the intestinal fluid is free or substantially free from available hydrochloric acid, e.g. do not release the medicament until the pH of the intestinal fluid is at least about 5.56 or higher.
Commercially available magnesium hydroxide and magnesium oxide can be used in the enteric coated dosage units of the present invention. Their reaction with the carbon dioxide gas, however, may be somewhat retarded or not as rapid as desired in some cases, due to the fact that the pH of the fluids in the duodenum and lower intestinal tract is for the most part nearly neutral.
ice
In continued investigations in this field, it was discovered that a highly reactive finely divided dry magnesium hydroxide product could be obtained by drying aqueous magnesium hydroxide, i.e. magnesia magma, in the frozen state. The resulting freeze-dried magnesium hydroxide product retains most of original reactivity of the magma and is preferred for use in the enteric coated dosage units of the present invention.
The freeze-dried magnesium hydroxide product, due to its high activity, can also be used to advantage where desired as a simple antacid or laxative in dosage unit form without the enteric coating. The highly reactive freeze-dried product, for example, can be sealed in strips, either foil or transparent, in antacid or laxative doses. The dosage units, which can be flavored, can be administered as such or added to water to make an instant Milk of Magnesia type product. Both the enteric coated products and the freeze-dried product have an advantage over liquid products in that they pose no freezing problem during transportation in winter.
The following examples will serve to illustrate the invention.
EXAMPLE I grams of magnesia magma, e.g. made up of about 30% Mg(OH) and 70% H O, is frozen in a flask suspended in an acetone-Dry Ice mixture. After completely frozen, the flask is removed from the freezing mixture and a high vacuum applied so that the magma dries from the frozen state without melting. After completely dry, the vacuum is disconnected. The resulting freeze-dried magnesium hydroxide product is next tabletted by conventional means with starch and lactose or like pharmaceutical diluents along with binders and lubricants to form compressed tablets containing about 0.5 gm. of magnesium hydroxide per tablet. The tablets are then finally enteric coated with cellulose acetate phthalate or other suitable enteric coating so that when administered orally the intestinal fluid does not reach the tablet contents until the pH of the fluid is at least about 5.5-6 or higher, i.e. when there is substantially no free HCl present in the fluid.
EXAMPLE II This example is in accordance with Example I, except that commercial magnesium hydroxide (NF) is used in place of the freeze-dried magnesium hydroxide product. As in Example I, the tablet is enteric coated to provide for the release of the magnesium hydroxide after the pH of the intestinal fluid reaches at least about pH 5.5-6.
EXAMPLE III This example is in accordance with Example II, except that magnesium oxide is used in place of magnesium hydroxide.
EXAMPLE IV This example is in accordance with Example I, except that the tablet containing the freeze-dried magnesium hydroxide product is not enteric coated. With tablets 01. this type, the dose as an antacid is 12 tablets and the dose as a laxative is 3-4 tablets.
EXAMPLE V flatulence-causing gases through the intestine as magnesium carbonate in solid form. it also will be apparent from the above that as the dosage units disintegrate and release the magnesium hydroxide or oxide medicamenis only after the pH of the intestinal contents are above the value Where available hydrochloric acid would be negligible, no significant amounts of soluble magnesium compounds form. This last feature as noted above, is important Where side effects caused by absorption of magnesium are to be avoided and laxative action is contraindicated.
I claim:
1. An enteric coated dosage unit containing as an essential ingredient a medicament selected from the group consisting of magnesium hydroxide and magnesium oxide in an amount sufficient to provide relief from discomfort due to excessive carbon dioxide in the human intestinal tract, said enteric coating being an enteric coating Which will release the medicament in the intestinal tract when the intestinal fluid is substantially free from hydrochloric acid.
2. A dosage unit in accordance with claim 1, Where the medicament is freeze-dried magnesium hydroxide and the enteric coating does not release the magnesium hydroxide in the intestinal tract until the intestinal fluid reaches a pH of at least about 5.5-6.
3. The method of providing relief from discomfort due to excessive carbon dioxide in the intestinal tract Without laxative action which comprises orally administering to persons an enteric coated tablet containin as an essential ingredient a medicament in an effective amount selected from the group consisting of magnesium hydroxide and magnesium oxide, said enteric coating being an enteric coating Which Will release the medica' ment in the intestinal tract When the intestinal fluid is substantially free from hydrochloric acid.
4. A dosage unit adaptable for use as an antacid and laxative consisting essentially of magnesium hydroxide prepared by freeze-drying Milk of Magnesia.
References Cited UNITED STATES PATENTS 5/1951 Zichis 167-785 3,081,233 3/1963 Enz 16782.5 3,094,464 6/1963 Joullie 167-825
Claims (1)
1. AN ENTERIC COATED DOSAGE UNIT CONTAINING AS AN ESSENTIAL INGREDIENT A MEDICAMENT SELECTED FROM THE GROUP CONSISTING OF MAGNESIUM HYDROXIDE AND MANGESIUM OXIDE IN AN AMOUNT SUFFICIENT TO PROVIDE RELIEF FROM DISCOMFORT DUE TO EXCESSIVE CARBON DIOXIDE IN THE HUMAN INTESTINAL TRACT, SAID ENTERIC COATING BEING AN ENTERIC COATING WHICH WILL RELEASE THE MEDICAMENT IN THE INTESTINAL TRACT WHEN THE INTESTINAL FLUID IS SUBSTANTIALLY FREE FROM HYDROCHLORIC ACID.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE656526D BE656526A (en) | 1963-12-03 | ||
| US327842A US3369968A (en) | 1963-12-03 | 1963-12-03 | Composition and method of absorbing gas in teh intestine |
| FR997116A FR4265M (en) | 1963-12-03 | 1964-12-02 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US327842A US3369968A (en) | 1963-12-03 | 1963-12-03 | Composition and method of absorbing gas in teh intestine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3369968A true US3369968A (en) | 1968-02-20 |
Family
ID=23278304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US327842A Expired - Lifetime US3369968A (en) | 1963-12-03 | 1963-12-03 | Composition and method of absorbing gas in teh intestine |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US3369968A (en) |
| BE (1) | BE656526A (en) |
| FR (1) | FR4265M (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4042685A (en) * | 1974-05-15 | 1977-08-16 | Walton John Smith | Milk of magnesia |
| WO1996002261A1 (en) * | 1994-07-19 | 1996-02-01 | Sterling Winthrop Inc. | Use of magnesium hydroxide as a stool softener |
| US20140127296A1 (en) * | 2012-11-05 | 2014-05-08 | Kenneth John Tibbs | Pharmaceutical preparation and method for treatment of diabetes |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308126D0 (en) * | 1983-03-24 | 1983-05-05 | Bloch M | Pharmaceutical compositions |
| DE3402878A1 (en) * | 1984-01-27 | 1985-08-01 | Algina AG, Zug | MEDICINAL PRODUCTS AND THE USE OF HEAVY-SOLUBLE CALCIUM AND / OR MAGNESIUM COMPOUNDS AS MEDICINAL PRODUCTS |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2552360A (en) * | 1945-01-10 | 1951-05-08 | Zichis Joseph | Method of and apparatus for dehydrating materials |
| US3081233A (en) * | 1960-08-08 | 1963-03-12 | Upjohn Co | Enteric-coated pilules |
| US3094464A (en) * | 1960-04-01 | 1963-06-18 | Rech S Et Propagande Scient | Aspirin-antacid polysiloxane tablet |
-
0
- BE BE656526D patent/BE656526A/xx unknown
-
1963
- 1963-12-03 US US327842A patent/US3369968A/en not_active Expired - Lifetime
-
1964
- 1964-12-02 FR FR997116A patent/FR4265M/fr not_active Expired
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2552360A (en) * | 1945-01-10 | 1951-05-08 | Zichis Joseph | Method of and apparatus for dehydrating materials |
| US3094464A (en) * | 1960-04-01 | 1963-06-18 | Rech S Et Propagande Scient | Aspirin-antacid polysiloxane tablet |
| US3081233A (en) * | 1960-08-08 | 1963-03-12 | Upjohn Co | Enteric-coated pilules |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4042685A (en) * | 1974-05-15 | 1977-08-16 | Walton John Smith | Milk of magnesia |
| WO1996002261A1 (en) * | 1994-07-19 | 1996-02-01 | Sterling Winthrop Inc. | Use of magnesium hydroxide as a stool softener |
| US20140127296A1 (en) * | 2012-11-05 | 2014-05-08 | Kenneth John Tibbs | Pharmaceutical preparation and method for treatment of diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| BE656526A (en) | |
| FR4265M (en) | 1966-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4956386A (en) | Pharmaceutical compositions and process for their preparation | |
| US5023245A (en) | Improved niacin formulation | |
| US3131123A (en) | Enteric tablets and manufacture thereof | |
| CA1040532A (en) | Process for producing solid bismuth-containing pharmaceutical compositions | |
| KR880002529A (en) | Pharmaceutical composition for the treatment of thrombosis and preparation method thereof | |
| DK146434B (en) | PROCEDURE FOR THE PREPARATION OF TABLETS OR SUPPLIES WITH LONG-TERM RELEASE | |
| Gilat et al. | A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis: an Israeli multicenter trial | |
| US5776431A (en) | Water-soluble aspirin composition | |
| Leonards et al. | Effect of pharmaceutical formulation on gastrointestinal bleeding from aspirin tablets | |
| JPH0625064B2 (en) | Controlled release potassium chloride | |
| EP2598123A1 (en) | Compositions | |
| KR100238565B1 (en) | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress | |
| US3369968A (en) | Composition and method of absorbing gas in teh intestine | |
| US4225614A (en) | Method of treatment for mucocutaneous herpes simplex infections | |
| US20070092561A1 (en) | Water-Soluble Aspirin Composition | |
| US4721716A (en) | Method for desensitizing the gastrointestinal tract from food allergies | |
| JPS6210013A (en) | Remedy and preventive for gastritis | |
| JPH0656677A (en) | Antacid composition | |
| US3655883A (en) | Water soluble magnesium-aluminum antacid composition | |
| US2940898A (en) | Aluminum salt antacid compositions and method of using same | |
| Harris et al. | Gastrointestinal decontamination: which method is best? | |
| Necheles et al. | Peptic Ulcer in Man Part 4. A New Antacid Made To Meet Requirements Of Antacid Therapy, Chemical And Laboratory Work | |
| US3155576A (en) | Ulcer therapy composition and method of using same | |
| Fantus | Peroral administration of colloidal contrast medium in cholecystography | |
| CA1111766A (en) | Controlled antacid delivery form and method of treatment therewith |